Article Abstract

Adjuvant chemotherapy with gemcitabine plus erlotinib vs. gemcitabine alone for patients with resected pancreatic ductal adenocarcinoma: is there a role for erlotinib?—review of the open label phase III trial CONKO 005

Authors: Mathilde Wisniewski, Pierre-Alain Placide, Sandra Granier, Yacoub Al Shatti, Shuaib Al Qalaf, Mohamed Bouattour, Michele Lamuraglia, Pascal Hammel

Abstract

Sinn et al. (1) report the results of a multicenter trial comparing the combination of gemcitabine and erlotinib with gemcitabine alone for adjuvant therapy in 436 patients who underwent R0 resection for pancreatic ductal carcinoma (PDAC).

Article Options

Download Citation